Mounjaro · Zepbound
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
A persistent stacking question of the GLP-1 era: whether adding a growth-hormone secretagogue to tirzepatide or retatrutide blunts the lean-mass loss that comes with the weight loss. Trial data establishes the magnitude of that loss, not a drug-specific excess; the rest is untested community theory.
A dual GLP-1/GIP receptor agonist and the most potent of the approved class. Runs 2.5–15 mg weekly across both brands; no FDA-approved oral version exists as of mid-2026 despite "tirzepatide tablets" circulating online.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published start, titration steps, and target dose, shown as reference. Included with membership.
Reference values as published in the research record — not a recommendation, instruction, or dose suggestion for any person. Not medical advice.
The live calculator — enter any vial size, diluent volume, and syringe size to see the draw computed — is included with membership.